Nuvalent CFO Form 4 details November 2025 insider trades
Rhea-AI Filing Summary
Nuvalent, Inc. (NUVL) filed a Form 4 for its Chief Financial Officer detailing option exercises and stock sales in November 2025. On November 17, 2025, the CFO exercised stock options for 6,875 Class A shares at $6.89 and 13,125 shares at $72.35, then sold multiple blocks of Class A Common Stock at weighted average prices ranging from $93.8 to $103.68. On November 18, 2025, additional options for 729 shares at $72.35 were exercised, with share sales at weighted average prices of $103.61 and $104.54. After these transactions, the CFO directly owned 61,734 Class A shares and held stock options covering 29,101 and 33,646 shares. All reported trades were made under a Rule 10b5-1 trading plan adopted on December 12, 2024.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 729 | $0.00 | -- |
| Exercise | Class A Common Stock | 729 | $72.35 | $53K |
| Sale | Class A Common Stock | 220 | $103.61 | $23K |
| Sale | Class A Common Stock | 509 | $104.54 | $53K |
| Exercise | Stock Option (Right to Buy) | 6,875 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 13,125 | $0.00 | -- |
| Exercise | Class A Common Stock | 6,875 | $6.89 | $47K |
| Exercise | Class A Common Stock | 13,125 | $72.35 | $950K |
| Sale | Class A Common Stock | 3,609 | $93.80 | $339K |
| Sale | Class A Common Stock | 3,266 | $95.12 | $311K |
| Sale | Class A Common Stock | 4,496 | $100.58 | $452K |
| Sale | Class A Common Stock | 3,194 | $102.13 | $326K |
| Sale | Class A Common Stock | 5,055 | $103.27 | $522K |
| Sale | Class A Common Stock | 380 | $103.68 | $39K |
Footnotes (1)
- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.73 to $94.38, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (9) of this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.93 to $95.58, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.11 to $101.07, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.57 to $102.47, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.60 to $103.54, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.65 to $103.79, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.14 to $103.96, inclusive. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.25 to $105.12, inclusive. The shares underlying this option vest as follows: 25% of the shares vested on April 29, 2022, and the remainder have vested or shall vest over the three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date. The shares underlying this option have vested or shall vest over the four years following January 5, 2024 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
FAQ
What does the Nuvalent (NUVL) Form 4 disclose about the CFO?
The Form 4 shows that Nuvalent’s Chief Financial Officer executed multiple stock option exercises and related sales of Class A Common Stock in November 2025 and now directly owns 61,734 shares.
What stock option exercises did the Nuvalent (NUVL) CFO report?
The CFO exercised options for 6,875 shares at $6.89 and 13,125 shares at $72.35 on November 17, 2025, and 729 shares at $72.35 on November 18, 2025.
Were the Nuvalent (NUVL) CFO trades made under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024.
How do the Nuvalent (NUVL) option grants vest according to the Form 4?
One option grant vested 25% on April 29, 2022, with the remainder in equal monthly installments over three years, and another vests in equal monthly installments over four years following January 5, 2024, subject to continued service.